Related Experiment Video
Updated: Jul 10, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
An improved PID switching control strategy for type 1 diabetes.
Gianni Marchetti1, Massimiliano Barolo, Lois Jovanovic
1Department of Chemical Engineering Principles & Practice, Università di Padova, Padova, Italy.
Summary
This study introduces an improved artificial pancreas control strategy using PID control for better blood glucose management. The novel approach enhances safety and effectiveness in simulations, paving the way for real-world applications.
Area of Science:
- Biomedical Engineering
- Control Systems Engineering
- Computational Physiology
Background:
- Developing a practical artificial pancreas for ambulatory use requires robust closed-loop control.
- Existing control strategies face challenges with meal disturbances, sensor noise, and physiological variability.
Purpose of the Study:
- To propose and evaluate an improved Proportional-Integral-Derivative (PID) control strategy for blood glucose regulation in an artificial pancreas system.
- To enhance the safety and efficacy of artificial pancreas control under realistic ambulatory conditions.
Main Methods:
- In silico evaluation using the Hovorka et al. physiological model.
- Implementation of a novel PID control strategy featuring a meal-initiated switching mechanism.
- Inclusion of a time-varying setpoint, noise/derivative filters, and a systematic tuning approach.
Main Results:
- The proposed PID control strategy demonstrated favorable performance compared to alternatives in simulations.
- Effective management of blood glucose levels was observed under various challenging conditions, including meal intake and altered insulin sensitivity.
- The control strategy showed robustness against incorrect carbohydrate estimates and sensor noise.
Conclusions:
- The developed PID control strategy represents a significant advancement towards a practical artificial pancreas.
- The strategy's effectiveness in simulations suggests its potential for improving glycemic control in ambulatory individuals.
- Further validation is warranted for real-world clinical application of this artificial pancreas control system.
Related Concept Videos
01:19PID Controller
Proportional-Integral-Derivative (PID) controllers are widely used in various control systems to enhance stability and performance. In a thermostat, it adjusts heating or cooling based on the temperature difference between the actual and desired levels. They are often used in automotive speed systems, effectively managing sudden speed changes while maintaining a constant speed under varying conditions. On the other hand, PI controllers, commonly employed in voltage regulation, enhance stability...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...